Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer

Background: IMpassion130 trial results led to approval of first-line atezolizumab plus nab-paclitaxel for PD-L1-positive advanced triple-negative breast cancer (aTNBC). The global single-arm EL1SSAR study (NCT04148911) enrolled a broader patient population to elucidate outcomes in routine practice....

詳細記述

書誌詳細

出版年:	Breast
主要な著者:	L. Gianni, S. Delaloge, E. Ciruelos, O. Trédan, C. Castañeda, M.H. Abreu, I. Paris, M. Colleoni, G. Scandurra, M. Kwiatkowski, N. Antone, V. Gregorc, P. Tagliaferri, S. Borštnar, I. Blancas, M. Raimondo, M. Alfie, C. Arce-Salinas, P.S. Madeira, Y.G. Lin, C. Ye, K. Koli, J. Mouta, M. Martin
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2026-08-01
主題:	PD-L1 Immune checkpoint inhibitor Triple-negative breast cancer SP142 ECOG
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S0960977626001463